Abstracts tagged "Nephritis"

Abstract Number: 0837 • ACR Convergence 2020
Deletion of miR-223 Exacerbates Lupus Nephritis by Targeting S1pr1 in Faslpr/lpr Mice
Sumie Hiramatsu Asano¹, Tomoyuki Mukai², Yoshitaka Morita³ and Jun Wada⁴, ¹Kawasaki Medical School/Department of Rheumatology, Kurashiki city, Japan, ²Kawasaki Medical School, Kurashiki-shi, Okayama, Japan, ³Kawasaki Medical School/Department of Rheumatology, Kurashiki, Okayama, Japan, ⁴Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences., Okayama city, Japan
Background/Purpose: To identify new candidate genes regulated by micro RNAs (miRNAs) and involved in the pathogenesis of systemic lupus erythematosus (SLE), we integrated miRNA and…
Abstract Number: 0846 • ACR Convergence 2020
MHC Class I Epitopes Derived from Autoantibody Variable Regions, Conjugated to Synthetic Oligodeoxynuleotides, Induce Cytotoxic T Cells That Deplete Autoreactive B Cells and Ameliorate Murine Lupus
Ram Singh¹, ¹UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: B cell depletion or modulation is emerging as a major treatment modality for autoimmune diseases. However, the current treatments to accomplish this non-specifically target…
Abstract Number: 0868 • ACR Convergence 2020
Impact of Proteinuria on the Clearance of Monoclonal Antibodies: Potential Clinical Implications
Justin Penzenstadler¹, Jianmeng Chen², Aaron Park², Rosemarie Neuner², Aliza Thompson², Lei He², Ping Ji², Nikolay Nikolov² and Chandrahas Sahajwalla², ¹FDA, F, ²FDA, Silver spring
Background/Purpose: In general, renal elimination is minimal for therapeutic proteins with a molecular weight more than 69 KDa. However, in patients with proteinuria, there is…
Abstract Number: 0988 • ACR Convergence 2020
Two-Year Results from a Randomized, Controlled Study of Obinutuzumab for Proliferative Lupus Nephritis
Richard Furie¹, Gustavo Aroca², Analia Alvarez³, Hilda Fragoso-Loyo⁴, Elizabeth Zuta Santillan⁵, Brad Rovin⁶, Paul Brunetta⁷, Thomas Schindler⁸, Imran Hassan⁹, Matthew Cascino¹⁰, Jay Garg¹⁰ and Ana Malvar¹¹, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²Simon Bolivar University y Clinica de la Costa, Barranquilla, Colombia, ³CEMIC, Buenos Aires, Argentina, ⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Instituto de Ginecología y Reproducción, Lima, Peru, ⁶The Ohio State University, Columbus, ⁷Genentech, Inc., South San Francisco, ⁸F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁹Hoffmann-La Roche Ltd, Mississauga, Canada, ¹⁰Genentech, Inc., South San Francisco, CA, ¹¹Organizacion Medica de Investigacion, Buenos Aires, Argentina
Background/Purpose: NOBILITY demonstrated improved renal responses and complete B-cell depletion with the humanized type II anti-CD20 monoclonal antibody obinutuzumab (OBI) compared with placebo (PBO) through…
Abstract Number: 1673 • ACR Convergence 2020
Principles of Pediatric Lupus Nephritis in a Contemporary Multi-Center Cohort
Kathleen Vazzana¹, Ankana Daga², Beatrice Goilav³, Ekemini Ogbu⁴, Daryl Okamura⁵, Catherine Park⁶, Rebecca Sadun⁷, Emily Smitherman⁸, Brian Stotter⁹, Scott Wenderfer¹⁰ and Laura Lewandowski¹¹, ¹National Institute of Health/Children's National Hospital, Washington, DC, ²Harvard, Boston, MA, ³The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Seattle's Children's, Seattle, WA, ⁶Emory University, Atlanta, GA, ⁷Duke University, Durham, NC, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Washington University School of Medicine, St. Louis, MO, ¹⁰Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, ¹¹NIAMS, NIH, Rockville, MD
Background/Purpose: Lupus nephritis (LN) is a well-established and life-threatening manifestation of systemic lupus erythematosus (SLE) that is more common in children than adults. The demographics…
Abstract Number: 1807 • ACR Convergence 2020
The Extent of Tubulointerstitial Inflammation in Lupus Nephritis Identifies Two Distinctive Subgroups: Impact on Inflammation Characteristics and Prognosis in Patients with Lupus Nephritis
Sang Jin Lee¹, Eon Jeong Nam¹, Man-Hoon Han² and Yong Jin Kim², ¹Department of Internal Medicine, Kyungpook National University Hospital,, Daegu, Republic of Korea, ²Department of Pathology, Kyungpook National University Hospital,, Daegu, Republic of Korea
Background/Purpose: Lupus nephritis is common clinical manifestation and contributes significantly to mortality in systemic lupus erythematosus (SLE). Recently several studies has been reported that severity of…
Abstract Number: 1836 • ACR Convergence 2020
Alternative Renal Response Definitions in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis
Zahir Amoura¹, Philippe Remy², Luis Fernando Quintana Porras³, Laurent Chiche⁴, Dominique Chauveau⁵, Dario Roccatello⁶, Richard Furie⁷, Thomas Schindler⁸, Jay Garg⁹, Matthew Cascino⁹, Brad Rovin¹⁰ and Andrea Doria¹¹, ¹Hôpital Pitié-Salpêtrière, Paris, ²APHP Groupe Hospitalier Henri-Mondor, Creteil, France, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁴Hôpital Européen, Marseille, France, ⁵Hôpital Rangueil, Centre Hospitalier Univ de Toulouse, Toulouse, France, ⁶S Giovanni Hospital, Univ of Turin, Turin, Italy, ⁷Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁸F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁹Genentech, Inc., South San Francisco, CA, ¹⁰The Ohio State University, Columbus, ¹¹University of Padua, Padua, Italy
Background/Purpose: Obinutuzumab, a type II anti-CD20 mAb, resulted in rapid and complete B-cell depletion and improved renal responses in proliferative lupus nephritis (LN) in the…
Abstract Number: 077 • 2020 Pediatric Rheumatology Symposium
Tubulointerstitial Nephritis and Uveitis (TINU): A Pediatric Case Series with Longitudinal Followup
Deborah Stein ¹, Elizabeth Benoit ¹ and Mindy Lo¹, ¹Boston Children's Hospital, Boston
Background/Purpose: Tubulointerstitial nephritis and uveitis (TINU) syndrome is an uncommon condition that is likely under-recognized. The ideal treatment of both renal and ophthalmologic disease activity…
Abstract Number: 1899 • 2019 ACR/ARP Annual Meeting
sFlt-1, PlGF and VEGF in the Differential Diagnosis Between Active SLE Nephritis During Pregnancy and Preeclampsia
Guilherme De Jesus¹, Marcela Lacerda ¹, Bruna Rodrigues ¹, Flavia dos Santos ¹, Adriana Nascimento ¹, Luis Cristóvão Porto ¹, Nilson Ramires de Jesús ¹, Roger Levy ² and Evandro Klumb ¹, ¹Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²GlaxoSmithKline, Upper Providence, PA
Background/Purpose: Pregnancy in patients with SLE is associated with significant morbidity and mortality. SLE activity during pregnancy, specifically nephritis, makes the differential diagnosis with preeclampsia…
Abstract Number: 459 • 2018 ACR/ARHP Annual Meeting
Readmission Rate within 30 Days of Hospitalization Due to New Onset Lupus Nephritis and Associated Risk Factors: The Importance of Intravenous Pulse Methylprednisolone Therapy
Angel Alberto Herrera Guerra¹, Sampath Prahalad¹, Kelly A. Rouster-Stevens¹, Rouba Garro², Leah Bryan³ and Yin Hong⁴, ¹Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Pediatric Nephrology, Emory University School of Medicine, Atlanta, GA, ³Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁴Pathology, Children's Health Care of Atlanta, Atlanta, GA
Background/Purpose: There is a paucity of data regarding the early hospital readmission rates in newly diagnosed childhood lupus nephritis (cLN). We conducted a retrospective study…
Abstract Number: 748 • 2018 ACR/ARHP Annual Meeting
Long-Term Survival of Renal Transplantation Due to Lupus Nephritis. Comparative Study with Non-Autoimmune Transplantation. Study from a Single Center
Lara Sánchez-Bilbao¹, Belén Atienza-Mateo¹, José Luis Martín-Varillas¹, Marina de Cos-Gómez², Íñigo González-Mazón¹, Diana Prieto Peña³, Monica Calderón Goercke³, Juan Carlos Ruiz San Millán², Emilio Rodrigo Calabia², Miguel Angel González-Gay¹ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Nephrology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus, affecting up to 40% of patients. Unfortunately, about 20% of LN develop end…
Abstract Number: 749 • 2018 ACR/ARHP Annual Meeting
Is Lupus Nephritis Onset Delayed in Older Caucasian Females with Less Aggressive Pathology?
Cristina Arriens¹, Sixia Chen², David Karp³, Ramesh Saxena⁴, Joan T. Merrill¹ and Judith A. James⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁴Nephrology Division, UT Southwestern Medical Center, Dallas, TX, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Lupus Nephritis (LN) usually presents within 5 years of SLE diagnosis, however the minority of patients with late-occurring nephritis are poorly characterized. Factors associated…
Abstract Number: 765 • 2018 ACR/ARHP Annual Meeting
Predictors of End-Stage Renal Disease in Lupus Nephritis
Mery Deeb¹, Konstantinos Tselios², Dafna D Gladman², Jiandong Su² and Murray Urowitz³, ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toront, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: End-stage renal disease (ESRD) is the most important complication of lupus nephritis (LN) and greatly affects mortality. Its incidence has been estimated at 11%…
Abstract Number: 2698 • 2018 ACR/ARHP Annual Meeting
Renal Involvement in Mixed Connective Tissue Disease: A Single Center Experience
Eduardo Martín Nares¹, Silvia Eunice Ramírez Andrade², Luis Eduardo Morales Buenrostro², Norma Ofelia Uribe Uribe³, Laura R Cárdenas M³, Montserrat Reyes Macedo³ and Tatiana S. Rodriguez-Reyna¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Kidney injury in mixed connective tissue disease (MCTD) is an uncommon manifestation. Prevalence has been reported to be <4% in some cohorts. The frequency…
Abstract Number: 2621 • 2017 ACR/ARHP Annual Meeting
Minimal Renal Affection in Patients with Systemic LUPUS Erythematosus: Characteristics and Evolution
TC Salman-Monte¹, Eva Rodriguez², José Luis Arevalos³, María José Soler³, Clara Barrios³, Jordi Carbonell⁴ and Julio Pascual³, ¹Rheumatology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain, ²Nephrology, Hospital del Mar/ Parc de Salut Mar, Barcelona, Spain, ³Nephrology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain, ⁴Rheumatology Unit, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain
Background/Purpose: Lupus nephritis (LN) is the most common organ involvement in Systemic Lupus Erythematosus (SLE). Indications of renal biopsy (RB) are deterioration of renal function…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].